# Cronos Group Inc. Common Share (CRON.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$4.50, market value C$1.7 billion.

## Valuation
- **P/E (trailing): 17.3×** (5-yr avg 28.9×, 3-yr avg 28.9×). Cronos Group Inc. Common Share trades at 17.3× trailing earnings, well below its own five-year average of 28.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 6.7×**. Each dollar of revenue is priced at 6.7×.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.8×**. Enterprise value is 6.8× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 4.1%** (5-yr avg -4.0%). Free cash flow equals 4.1% of the market value, above its five-year average of -4.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 5.8%**. The inverse of the P/E: 5.8% of the price is earned each year.

## Profitability
- **Gross margin: 45.4%**. Cronos Group Inc. Common Share keeps 45.4% of revenue after the direct cost of what it sells.
- **Operating margin: 0.3%**. 0.3% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -6.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -0.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 0.2%**. Return on all capital, debt included, is 0.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 5.8%**. Each dollar of assets produces 5.8% of profit.

## Growth
- **Revenue growth (1 yr): 26.9%** (3-yr 19.4%/yr, 5-yr 26.2%/yr). Revenue grew 26.9% over the last year, against 26.2% a year compounded over five years.
- **EPS growth (1 yr): -125.1%**. Earnings per share fell 125.1%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Cronos Group Inc. Common Share holds more cash than debt.
- **Current ratio: 19.59** (quick 18.62). Current assets cover the next year's liabilities 19.59 times.
- **Altman Z-score: 20.65**. A Z-score of 20.65 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Cronos Group Inc. Common Share does not currently pay a dividend, but it returned 3.2% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): 30.4%** (YTD 25.0%, 3-mo 16.9%). The shares are up 30.4% over twelve months including dividends.
- **From 52-week high: -9.8%** (39.3% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.73** (volatility 44%). Beta of 0.73 against the S&P/TSX Composite: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRON.TO · Page: https://foliofundamentals.com/stocks/cron.to

Not investment advice.